Compare equities side by side
Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Today's biggest gainers and losers
Visual sector performance
NewAmsterdam Pharma is a clinical-stage biopharmaceutical company focused on developing obicetrapib, a novel oral CETP inhibitor for cardiovascular disease. The company is pre-revenue with Phase 3 trials (BROADWAY, BROOKLYN) targeting LDL-cholesterol reduction in high-risk patients, positioning for potential FDA approval in 2026-2027. With $500M+ cash runway and no debt, NAMS represents a binary regulatory catalyst play in the $15B+ lipid-lowering therapeutics market.
NAMS is developing a first-in-class oral CETP inhibitor with differentiated safety profile versus prior failed CETP inhibitors (torcetrapib, dalcetrapib). Obicetrapib demonstrated 50%+ LDL-C reduction in Phase 2b trials with favorable tolerability. Revenue model depends on FDA approval followed by commercial launch targeting 15-20M US patients on statins with inadequate LDL control or statin intolerance. Pricing power derives from clinical differentiation versus injectable PCSK9 inhibitors ($5,000-14,000 annual cost) and oral bempedoic acid. Estimated peak sales potential $2-4B annually based on 5-10% market penetration at $3,000-5,000 annual treatment cost. No current revenue; company burning $200M+ annually on Phase 3 trials and regulatory preparation.
Phase 3 BROADWAY trial interim data readouts (primary endpoint: LDL-C reduction at 12 weeks in statin-intolerant patients)
Phase 3 BROOKLYN trial cardiovascular outcomes data (MACE reduction versus placebo, estimated 2027-2028 readout)
FDA regulatory milestones: NDA submission timing, FDA acceptance, Advisory Committee meetings, approval decision
Partnership announcements for ex-US commercialization rights (Europe, Asia-Pacific territories)
Competitive developments in CETP inhibitor class or alternative LDL-lowering mechanisms (siRNA therapies, gene editing)
Cash runway updates and financing activities given $200M+ annual burn rate
CETP inhibitor class risk: Three prior CETP inhibitors failed (torcetrapib increased mortality, dalcetrapib/evacetrapib showed no cardiovascular benefit). Market skepticism persists despite obicetrapib's differentiated mechanism and safety profile.
Regulatory approval uncertainty: FDA may require cardiovascular outcomes data (BROOKLYN trial, 2027-2028) before approval rather than surrogate LDL-C endpoint alone, delaying commercialization 2-3 years.
Reimbursement pressure: Payers increasingly scrutinize high-cost lipid therapies. Medicare/commercial plans may impose restrictive prior authorization requiring statin failure documentation, limiting addressable market to 30-40% of target population.
Competitive landscape evolution: Inclisiran (siRNA, Novartis) gaining share with twice-yearly dosing. Oral PCSK9 inhibitors in development could obviate CETP mechanism advantage.
Amgen/Novartis PCSK9 inhibitors (Repatha, Praluent) established in market with proven cardiovascular outcomes data and expanding label indications. Oral convenience advantage may be insufficient if outcomes data delayed.
Bempedoic acid (Nexletol, Esperion) offers oral alternative at lower cost with recent cardiovascular outcomes data, though modest efficacy (15-20% LDL reduction versus 50%+ for obicetrapib).
Generic statins plus ezetimibe combination provides 60-70% LDL reduction at <$100 annual cost, limiting premium pricing power for novel agents.
Pipeline competition: Eli Lilly, Silence Therapeutics developing alternative LDL-lowering mechanisms with potentially superior efficacy or safety profiles.
Cash runway risk: $200M+ annual burn rate with $500M cash implies 2-2.5 year runway. If Phase 3 trials extend or FDA requires additional data, dilutive financing likely needed before revenue generation.
Clinical trial cost overruns: Cardiovascular outcomes trials historically exceed budget by 20-30%. BROOKLYN trial enrollment challenges or extended follow-up could accelerate cash consumption.
No revenue diversification: Single-asset company with 100% value dependent on obicetrapib approval. Pipeline remains pre-clinical with no near-term backup assets if lead program fails.
low - Clinical trial timelines and FDA regulatory processes are largely insulated from economic cycles. Post-approval revenue depends on healthcare spending, but cardiovascular therapeutics demonstrate recession-resistant demand given chronic disease management necessity. Prescription drug spending grows 3-5% annually regardless of GDP fluctuations. Primary sensitivity is to biotech funding environment affecting ability to raise capital if needed.
Rising interest rates negatively impact valuation through higher discount rates applied to distant future cash flows (2027+ revenue). Clinical-stage biotech valuations compress significantly in rising rate environments as risk-free alternatives become more attractive. However, strong cash position ($500M+) with 2+ year runway minimizes near-term financing risk. Rate sensitivity primarily affects stock multiple rather than fundamental business operations.
minimal - Zero debt capital structure eliminates refinancing risk. Company holds cash in short-duration instruments, benefiting modestly from higher yields on cash balances. No credit facility dependence for operations. Post-approval, commercial launch financing could involve debt, but current phase has no credit exposure.
growth - High-risk, high-reward binary event-driven investors focused on clinical-stage biotech. Attracts specialized healthcare hedge funds and biotech-focused growth funds willing to underwrite regulatory approval risk for potential 3-5x return on successful commercialization. Not suitable for value or income investors given pre-revenue status and negative cash flow. Momentum investors active around clinical data catalysts and regulatory milestones.
high - Clinical-stage biotech exhibits 60-80% annualized volatility typical of binary catalyst stocks. Single-day moves of 20-40% common around trial data releases and FDA decisions. Beta likely 1.5-2.0x versus biotech indices. Recent 75% one-year return reflects positive Phase 3 enrollment progress, but stock vulnerable to 50%+ drawdown on negative trial data or regulatory setback. Low float and institutional concentration amplify volatility.
